By Sabela Ojea

 

Bayer said Friday the Food and Drug Administration has approved its Ultravist injection to visualize breast lesions as an adjunct to mammographies or ultrasounds.

The pharmaceutical company said Ultravist-300 and -370 gives physicians a new imaging option beyond conventional mammographies.

"The new FDA-approved indication aligns with the recent increased focus on supplemental imaging needs for women at a higher risk for breast cancer," Bayer said.

Ultravist is an injection for intravenous and intra-arterial use.

 

Write to Sabela Ojea at sabela.ojea@wsj.com

 

(END) Dow Jones Newswires

June 23, 2023 14:21 ET (18:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Bayer Aktiengesellschaft (PK) 차트를 더 보려면 여기를 클릭.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Bayer Aktiengesellschaft (PK) 차트를 더 보려면 여기를 클릭.